Part-Time
IT Contractor
Posted on 8/23/2025
BigHat Biosciences
51-200 employees
ML-guided antibody discovery and engineering
No salary listed
San Mateo, CA, USA
Hybrid
Two days on-site per week in the Bay Area.
 IT & Security (2) |
|---|
| , |
- 5+ years of IT support or systems administration experience, preferably in a life sciences, technology, or startup environment.
- Strong expertise with Google Workspace (GSuite) administration, including user management and security best practices.
- Experience with AWS administration and security audits.
- Proven ability to manage and maintain hardware (laptops, lab computers, AV equipment).
- Familiarity with onboarding/offboarding processes and workflow automation.
- Strong problem-solving, documentation, and communication skills.
- Ability to work independently, manage priorities, and communicate effectively with cross-functional teams.
- Located in the Bay Area with availability to be on site ~2 days per week.
- Manage equipment ordering, setup, and lifecycle control, including conference room video/audio equipment and lab computer operating systems.
- Establish and maintain an equipment control process.
- Oversee GSuite administration, including group management, email routing, and security audits.
- Support onboarding and offboarding workflows, ensuring IT tasks are efficiently assigned and executed.
- Manage and audit access to third-party service accounts and AWS environments.
- Develop and maintain IT and engineering tutorials and documentation.
- Implement regular security audits and human workflow processes to ensure compliance and efficiency.
- Partner with the CIO to establish scalable IT processes as the organization grows.
BigHat Biosciences designs and develops antibody therapies by combining machine learning with synthetic biology. Its Milliner platform integrates a wet-lab workflow with AI to discover, engineer, and fully characterize hundreds of recombinant antibodies each week, enabling rapid development of safer and more effective treatments for hard-to-treat diseases such as certain infections and cancers. Unlike traditional antibody discovery, Milliner provides end-to-end screening, purification, and characterization in a high-throughput, weekly workflow, speeding up the path from concept to candidate. The company differentiates itself through its integrated platform that couples ML-driven design with synthetic biology experimentation, a focus on challenging diseases, and a culture that emphasizes work-life balance. Its goal is to deliver faster, safer antibody therapies to patients by expanding access to rapid discovery and engineering capabilities for healthcare providers and patients alike.
Company Size
51-200
Company Stage
Series B
Total Funding
$99.3M
Headquarters
San Carlos, California
Founded
2019
Simplify's Take
What believers are saying
- Synaffix ADC technology license expands pipeline into high-value oncology market segment.
- Series B $124M funding at $180M pre-money valuation enables platform scaling and hiring.
- Big pharma collaborations generate milestone payments and potential royalties on approved therapeutics.
What critics are saying
- CEO Mark DePristo resignation disrupts strategy execution during critical partnership scaling phase.
- Competitors Generate Biomedicines and AbCellera raise larger Series C rounds with superior valuations.
- Big pharma partners may internalize Milliner technology post-collaboration, eliminating licensing revenue streams.
What makes BigHat Biosciences unique
- Milliner platform synthesizes, purifies, and characterizes hundreds of antibodies weekly.
- Integrated wet lab with machine learning accelerates protein engineering versus traditional methods.
- Partnerships with Merck, J&J, AbbVie, and Amgen validate platform across multiple indications.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↑ 2%2 year growth
↑ 4%BigHat Biosciences raised $124 million in Series B funding led by S32 on April 28, 2025, with a pre-money valuation of $180 million. Participants included Amgen, Bristol-Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, Axial, Quain Investments, Andreessen Horowitz, 8VC, AME Cloud Ventures, and Kevin Moore.
Co-founder Mark DePristo has stepped down as CEO of Bighat Biosciences Inc. and is succeeded by fellow co-founder Peyton Greenside, who was president and CSO.
The Danish company Adcendo and Chinese company Multitude Therapeutics entered into a $1 billion deal to develop ADCs for the treatment of cancer; and in August, the FDA lifted a partial hold on a Phase 1 trial evaluating an ADC candidate developed by MediLink Therapeutics and BioNTech for the treatment of advanced or metastatic non-small cell lung cancer and breast cancer.
BigHat obtains access to Synaffix's site-specific ADC technology platform, and plans to combine Synaffix technology with its advanced ML antibody design platform to develop a new ADC pipeline
Similarly, AbbVie is collaborating with BigHat Biosciences to develop next-generation antibody therapeutics using the Milliner platform, focusing on oncology and neuroscience.